ArticlePlastic and reconstructive surgery. Global open2026
Effect of Tranexamic Acid on Inpatient Admission and Revision Rates in Primary Rhinoplasty: A Propensity Score-Matched Analysis.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tranexamic acid (TXA) is commonly used to reduce intraoperative bleeding and complications across surgical specialties. In rhinoplasty, prior studies indicate that TXA may reduce postoperative edema and ecchymosis, but its effects on revision rates and inpatient admissions remain unclear. This study evaluated TXA's efficacy in improving perioperative outcomes in primary rhinoplasty, analyzing admission rates, revisions, and other postoperative events. Methods: A retrospective cohort study was conducted using the TriNetX database of 133 million US medical records spanning 20 years. Patients undergoing primary rhinoplasty were identified, and outcomes up to 2 weeks postsurgery were compared between those administered TXA during rhinoplasty and those who were not. Revision rates within the first year were also analyzed. Propensity score-matching accounted for demographics, tobacco use, and comorbidities impacting bleeding risk. Results: We identified 1639 TXA and 33,221 non-TXA rhinoplasty patients. After matching, 1627 remained in each cohort. TXA patients had significantly lower inpatient admissions within 2 weeks postoperatively (odds ratio 0.492; Conclusions: Although TXA may not impact total blood loss enough to alter hemoglobin, its ability to minimize minor bleeding may improve intraoperative visibility, perhaps allowing for greater precision and reducing complication risks leading to revisions. Importantly, TXA did not increase adverse events, maintaining a favorable safety profile.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.